Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

We believe that Baxter stock is a good buying opportunity at the present time. BAX stock trades near $81 currently and it is, in fact, down 13% from its pre-Covid high of $93 in February 2020 – just before the coronavirus pandemic hit the world.

Should You Buy Baxter Stock Around $80?

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter presents critical care data at European Society of Intensive Care Medicine (ESICM) LIVES congress

Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress

Boston Scientific

Catalent

Hill-Rom Hlds

Medtronic

Intersect ENT

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxt

Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors

Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.

Baxter's (BAX) Premix Norepinephrine Now Available in U.S.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter announced the U.S. FDA approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine).

Baxter Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation

Colgate-Palmolive

Con Ed

Hormel Foods

Kellogg

Altria

Novartis

Northwest Natural Gas

Pinnacle West Capital

Reckitt Benckiser Group PLC

Unilever

Verizon

The market is 30% overvalued, and September is historically a time when many corrections begin. Fortunately, there are plenty of high-yield/low volatility blue chips to choose from.

14 High-Yield Blue Chips For A Rich Retirement

Baxter International is an appealing, qualitative business in the medical/pharma field. Following the latest acquisition plans, and the company's growth expectations, i'm taking a first look and a stance on the company.

Baxter - A Great Business, Could Be A 'Buy' With Hillrom

The stock price of Baxter International, a medical supplies company, has seen a rise of around 11% over the last twenty-one trading days, and it is up just 1% over the last twelve-month period. The rally in BAX stock over the recent past has been propelled by Hill-Rom accepting Baxter's acquisition.

What's Next For Baxter Stock After An 11% Rise In A Month?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hill-Rom Holdings, Inc. (NYSE: HRC) to Baxter International Inc. (NYSE: BAX). Under the terms of the proposed transaction, shareholders of Hill-Rom will receive only $156.00 in cash for each share of Hill-Rom that they own. KSF is seeking to determine whether this consideration and the process that led to it a

HILL-ROM HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hill-Rom Holdings, Inc. - HRC

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hill-Rom Holdings, Inc. ("Hill-Rom" or the "Company") (NYSE: HRC) in connection with the proposed acquisition of the Company by Baxter International Inc.("Baxter") (NYSE: BAX).

SHAREHOLDER ALERT: WeissLaw LLP Investigates Hill-Rom Holdings, Inc.

Baxter International Inc. (BAX) CEO Joe Almeida on Hillrom Acquisition - Conference Call Transcript

NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Hill-Rom Holdings, Inc. (NYSE: HRC) and its board of directors concerning the proposed acquisition of the company by Baxter International Inc. (NYSE: BAX).

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Hill-Rom Holdings, Inc.

AbbVie

Johnson & Johnson

UnitedHealth Group

Vertex Pharmaceuticals

Health Care Select Sector SPDR Fund

Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In  appeared first on InvestorPlace.

7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In

Baxter International Inc (NYSE: BAX) has agreed to acquire Hill-Rom Holdings Inc (NYSE: HRC) for $156.00 per share in cash, slightly higher than the earlier anticipated $150.  Related Content:   Baxter In Advanced Talks For $10B Hill Rom Buyout

Baxter to Acquire Hillrom At $156/Share: See The Highlights

DEERFIELD, Ill.& CHICAGO--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, and Hillrom (NYSE:HRC), a global medical technology leader, today announced that the companies have entered into a definitive agreement under which Baxter has agreed to acquire Hillrom for $156.00 per share in cash for a total equity value of approximately $10.5 billion and a total enterprise value of approximately $12.4 billion, including the assumption of debt. Hillrom b

Baxter to Acquire Hillrom, Expanding Connected Care and Medical Innovation Globally

Baxter International Inc.  BAX, +0.27% is in advanced talks to buy medical-equipment maker Hill-Rom Holdings Inc. for around $10 billion, according to people familiar with the matter.

The Wall Street Journal: Baxter International in advanced talks for Hill-Rom: report

The Baxter (NYSE: BAX) stock price will be in the spotlight on Monday as rumours of its Hill-Rom acquisition resurfaced. The stock closed at $73.97 on Friday, which was about 17% below the highest point this year.

Baxter stock price forecast amid Hill-Rom acquisition rumours

DEERFIELD, Ill., & NEW YORK--(BUSINESS WIRE)--The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), and UNICEF USA today announced a partnership to improve access to safe water in La Guajira, Colombia, one of the country's most water-challenged regions. A $1.5 million grant from the Foundation is fueling the three-year initiative aimed at ensuring thousands of children, adolescents, families and communities benefit from basic water, sanitation and h

The Baxter International Foundation and UNICEF USA Announce Partnership to Improve Water Security in Colombia

Campbell Soup

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

If you're an income investor, these investments should be on your radar right now.

Got $5,000? These 3 Solid Dividend Stocks Are Trading Near Their 52-Week Lows

The stock price of medical supplies company Baxter has seen a fall of 4% over the last five trading days, while it is also down over 7% in the last year. The recent fall came after the company announced its Q2 results and reports of it planning to acquire another medical devices company - Hill-Rom.

What's Next For Baxter Stock After A 4% Fall Last Week?

Digital Turbine

On Monday, in a recent interview on CNBC's “Trading Nation,” Chad Morganlander and Ari Wald said that the stocks in the energy and the travel sector did not perform that well due to the spike in the delta variant of the coronavirus. According to them, some of the stocks in the respective sectors were among […] The post Two traders pick two underperforming stocks to buy now appeared first on Invezz.

Two traders pick two underperforming stocks to buy now

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medical products company, is accelerating its companywide digital transformation across three strategic areas – developing new digital health solutions to personalize and improve patient care; creating seamless experiences for healthcare customers and patients; and modernizing technology capabilities and business processes to deliver data and insights to employees and customers. The company is working with Amazon W

Baxter Advances Enterprise Digital Transformation in Collaboration With AWS

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 in Laguna Beach, Calif. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:00 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through August 11, 2022. About Baxter Every day, millio

Baxter to Present at UBS Genomics 2.0 and MedTech Innovations Summit

Baxter International Inc. (BAX) CEO Joe Almeida on Q2 2021 Results - Earnings Call Transcript

News for Baxter Stock (BAX)